Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21657351 | 0.88 | PIK3CD (0.40) | PIK3CDIL6ST | |
| SCHEMBL21657352 | 0.83 | PIK3CD (0.42) | PIK3CDIL6ST | |
| SCHEMBL9926817 | 0.81 | PIK3CD (0.56) | PIK3CDIL6ST | |
| SCHEMBL10049353 | 0.81 | PIK3CD (0.56) | PIK3CDIL6ST | |
| SCHEMBL9926814 | 0.81 | PIK3CD (0.56) | PIK3CDIL6ST | |
| SCHEMBL10570167 | 0.77 | PIK3CD (0.41) | PIK3CDIL6ST | |
| SCHEMBL21583962 | 0.75 | PIK3CD (0.38) | PIK3CD | |
| SCHEMBL21657354 | 0.75 | PIK3CD (0.31) | PIK3CD | |
| SCHEMBL23663800 | 0.75 | PIK3CD (0.39) | PIK3CDIL6ST | |
| SCHEMBL2036191 | 0.75 | PIK3CD (0.50) | PIK3CDIL6ST |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-3805231-A1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| WO-2021000925-A1 | PYRROLO [2, 3-b] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-01-07 | — | — | WO | disclosed |
| WO-2020020385-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION | 上海翰森生物医药科技有限公司 | 2020-01-30 | — | — | WO | disclosed |
| WO-2019228341-A1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 江苏豪森药业集团有限公司 (CN) | 2019-12-05 | — | — | WO | disclosed |
| EP-2485314-A1 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary cell | Mitsubishi Chemical Corporation (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-8178246-B2 | Nonaqueous electrolyte solution, nonaqueous electrolyte secondary cell, and carbonate compounds | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-05-15 | — | — | US | disclosed |
| EP-2339684-A2 | Nonaqueous electrolytic solution, nonaqueous electrolyte secondary cell, and carbonate compounds | Mitsubishi Chemical Corporation (JP) | 2011-06-29 | — | — | EP | disclosed |
| US-20090253048-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY CELL, AND CARBONATE COMPOUNDS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-10-08 | — | — | US | disclosed |
| CN-101218706-A | Nonaqueous electrolyte solution, nonaqueous electrolyte secondary battery, and carbonate compound | MITSUBISHI CHEM CORP (JP) | 2008-07-09 | — | — | CN | disclosed |
| EP-1890357-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY BATTERY AND CARBONATE COMPOUND | Mitsubishi Chemical Corporation (JP) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253048-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY CELL, AND CARBONATE COMPOUNDS | SLC9A1, NHERF1, CA2 | PIK3CD 2191/4885IL6ST 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.